Cadila Pharmaceuticals Ltd has announced an agreement with Norway-based Inven2's start-up, Serca Pharmaceuticals, to develop a new treatments for heart patients.
The new drug is based on an invention by Professor Kjetil Taskén and co-workers at the University of Oslo and the Oslo University Hospital, an official statement said.
Serca's drug is aiming to help patients from developing secondary damage from cardiac disease, which is an unmet medical need. SERCA Pharmaceuticals will develop a drug treatment for injuries that occur when treating myocardial infarction, the statement said.